Literature DB >> 11266942

FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression.

V Brinkmann1, S Chen, L Feng, D Pinschewer, Z Nikolova, R Hof.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11266942     DOI： 10.1016/s0041-1345(00)02126-6

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  20 in total

Review 1.  The therapeutic potential of modulating the ceramide/sphingomyelin pathway.

Authors:  Richard Kolesnick
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 2.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 3.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 4.  The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an "immature" vascular maturation factor to a "mature" mediator of lymphocyte behavior and function.

Authors:  Michael D Davis; John H Kehrl
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

5.  Ovariectomy induces bone loss via microbial-dependent trafficking of intestinal TNF+ T cells and Th17 cells.

Authors:  Mingcan Yu; Subhashis Pal; Cameron W Paterson; Jau-Yi Li; Abdul Malik Tyagi; Jonathan Adams; Craig M Coopersmith; M Neale Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

Review 6.  Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress.

Authors:  Joel S Karliner
Journal:  Biochim Biophys Acta       Date:  2012-06-23

7.  FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

Authors:  Qing Liu; Xiaobin Zhao; Frank Frissora; Yihui Ma; Ramasamy Santhanam; David Jarjoura; Amy Lehman; Danilo Perrotti; Ching-Shih Chen; James T Dalton; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-08-29       Impact factor: 22.113

8.  S1P1 Contributes to Endotoxin-enhanced B-Cell Functions Involved in Hypersensitivity Pneumonitis.

Authors:  Carole-Ann Huppé; Pascale Blais-Lecours; Emilie Bernatchez; Jean-François Lauzon-Joset; Caroline Duchaine; Hugh Rosen; Geneviève Dion; Kelly M McNagny; Marie-Renée Blanchet; Mathieu C Morissette; David Marsolais
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

Review 9.  Targeting cells in motion: migrating toward improved therapies.

Authors:  Jason W Griffith; Andrew D Luster
Journal:  Eur J Immunol       Date:  2013-05-13       Impact factor: 5.532

Review 10.  Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system.

Authors:  Edward J Goetzl; Wengang Wang; Christine McGiffert; Mei-Chuan Huang; Markus H Gräler
Journal:  J Cell Biochem       Date:  2004-08-15       Impact factor: 4.429
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.